New Zealand · Delayed Price · Currency is NZD EBOS Group Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 13% to AUD 6.8 billion, with underlying EBITDA up 3.2% and strong segment performance in Healthcare and Animal Care. FY 2026 guidance is reaffirmed, with margin and cash flow improvements expected as the DC Renewal Program nears completion and productivity rises.
Fiscal Year 2025
-
The meeting reviewed strong revenue growth and strategic investments, but addressed challenges from the loss of a major contract, margin pressures, and a significant share price decline. Executive incentives were updated to better align with shareholder interests, and all board resolutions proceeded to vote.
-
Solid organic growth and strategic acquisitions drove a 12% revenue and 7.5% EBITDA increase, despite the loss of a major contract. Competitive pressures and soft consumer demand persist, but guidance targets 7% EBITDA growth in FY 2026, with continued investment in infrastructure and cost management.
-
Underlying revenue rose 9.5% and EBITDA 7% in H1 FY25, with strong growth in healthcare and animal care segments, cost savings, and new customer wins offsetting the loss of the Chemist Warehouse contract. FY25 EBITDA guidance of AUD 575–600 million was reiterated.
Fiscal Year 2024
-
Strong financial growth was reported, with revenue surpassing AUD 13 billion and dividends up 7.7%. Board renewal progressed, ESG initiatives advanced, and strategic acquisitions continued. All resolutions were presented without significant opposition, and management expressed confidence in future growth.
-
Revenue grew 7.8% to AUD 13.2B, underlying EBITDA rose 7.3% to AUD 624M, and EPS increased 6.8%. FY 2025 guidance targets AUD 575–600M EBITDA, with cost savings and new pharmacy revenues expected to offset the end of the Chemist Warehouse contract.